fda warning compounded semaglutide safety 2024 2025 for weight loss | Blog New Novo Nordisk initiatives support
Description
Contact us at BloomMD to learn more about your options!
GLP-1 agonists are shockingly expensive given that they are not a great breakthrough
GLP-3 (Retatrutide) is an experimental peptide that activates GLP-1, GIP, and glucagon receptors
Many weight loss programs overlook the importance of muscle preservation, which can ultimately damage metabolism and make long-term results harder to maintain
This matters more here than in a typical fat loss phase
For retailers and CPG brands, the challenge and opportunity lies in meeting these consumers precisely where they are along the weight-loss journey, engagin
